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ARTICLE

Standardizing CYP2D6 Genotype to Phenotype
Translation: Consensus Recommendations from the
Clinical Pharmacogenetics Implementation Consortium
and Dutch Pharmacogenetics Working Group
Kelly E. Caudle1,*, Katrin Sangkuhl2, Michelle Whirl-Carrillo2, Jesse J. Swen3, Cyrine E. Haidar1, Teri E. Klein2, Roseann S. Gammal1,4,
Mary V. Relling1, Stuart A. Scott5,6, Daniel L. Hertz7, Henk-Jan Guchelaar3 and Andrea Gaedigk8,9

Translating CYP2D6 genotype to metabolizer phenotype is not standardized across clinical laboratories offering pharmacogenetic (PGx) testing and PGx clinical practice guidelines, such as the Clinical Pharmacogenetics Implementation Consortium
(CPIC) and the Dutch Pharmacogenetics Working Group (DPWG). The genotype to phenotype translation discordance between
laboratories and guidelines can cause discordant cytochrome P450 2D6 (CYP2D6) phenotype assignments and, thus lead to
inconsistent therapeutic recommendations and confusion among patients and clinicians. A modified-Delphi method was
used to obtain consensus for a uniform system for translating CYP2D6 genotype to phenotype among a panel of international CYP2D6 experts. Experts with diverse involvement in CYP2D6 interpretation (clinicians, researchers, genetic testing
laboratorians, and PGx implementers; n = 37) participated in conference calls and surveys. After completion of 7 surveys,
a consensus (> 70%) was reached with 82% of the CYP2D6 experts agreeing to the final CYP2D6 genotype to phenotype
translation method. Broad adoption of the proposed CYP2D6 genotype to phenotype translation method by guideline developers, such as CPIC and DPWG, and clinical laboratories as well as researchers will result in more consistent interpretation of
CYP2D6 genotype.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔ Translating CYP2D6 genotype to metabolizer phenotype is
not standardized across clinical laboratories offering pharmacogenetic (PGx) testing and PGx clinical practice guidelines.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔ The purpose of this project was to harmonize the systems used by the Clinical Pharmacogenetics Implementation
Consortium (CPIC) and the Dutch Pharmacogenetics
Working Group (DPWG) and reach consensus among an international panel of CYP2D6 experts regarding the standardization of how to translate CYP2D6 genotype to phenotype.

Cytochrome P450 2D6 (CYP2D6) is directly involved in the
metabolism of ~ 20% of currently approved medications,1 and
genetic variation in the CYP2D6 gene has been implicated in
the efficacy and/or toxicity of many drugs. Consequently,
the highly polymorphic CYP2D6 gene is the focus of several
Clinical Pharmacogenetics Implementation Consortium (CPIC)
1

WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔ We engaged a diverse group of international CYP2D6
experts to establish a standardized method for translating
CYP2D6 genotype to metabolizer phenotype.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?
✔ Broad adoption of the proposed CYP2D6 genotype to
phenotype translation method by guideline developers,
such as the CPIC and DPWG, and clinical laboratories as
well as researchers will result in more consistent interpretation of CYP2D6 genotype.

and/or Dutch Pharmacogenetics Working Group (DPWG)
clinical practice guidelines on 15 widely used medications,
including selective serotonin reuptake inhibitors, tricyclic antidepressants, atomoxetine, codeine, tramadol, tamoxifen, ondansetron, and tropisetron.2–8 Recently, the CPIC and DPWG
reported some discrepancies in their guidelines, primarily
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related to how certain CYP2D6 genotypes or diplotypes (from
here on referred to as “genotype”) were translated into metabolizer phenotype or metabolizer status (from here on referred
to as “phenotype”).9 Figure 1 describes the process used to
translate identified CYP2D6 genetic variants into phenotypes.
Given that the clinical recommendations for CYP2D6 in the
CPIC and DPWG guidelines are based on phenotype, the assignment of CYP2D6 phenotype based on genotype is a critical aspect for consistent clinical implementation.
Translating CYP2D6 genotype to phenotype is also not
standardized across clinical laboratories offering pharmacogenetic (PGx) testing. Current systems used to translate
genotype to phenotype rely on the star (*) allele nomenclature (defining which variant(s) are present in an allele), and
the assignment of function to the star alleles (i.e., increased,
normal, decreased, or no function) with inferring phenotype
based on the identified genotype. Some systems utilize
the activity score (AS) system for assignment of phenotype
where each allele is assigned an “activity value” ranging from
0−1 (e.g., 0 for no function, 0.5 for decreased function, and
1.0 for normal function).10 In addition, given that the CYP2D6
allele can also have variable copy number, the activity value
of an allele is multiplied by the number of gene copies (i.e.,
×2, ×3, etc.) if copy number is known. If copy number is
not known, a sample maybe defaulted to ×2 assignment or
shown as xN. As such, the CYP2D6 AS is the sum of the
activity values assigned to each allele10 (Figure 1). Within

the CPIC guidelines, the CYP2D6 AS is then translated into a
phenotype using the following classification system: individuals with an AS of 0 are poor metabolizers (PMs), those with
a score of 0.5 are intermediate metabolizers (IMs), those
with a score of 1.0, 1.5, and 2.0 are normal metabolizers
(NMs), and those with a score > 2 are ultrarapid metabolizers
(UMs; later referred to as the “CPIC method”; Table 1).
Although the CPIC guidelines and some clinical laboratories categorize an AS of 1.0 as a CYP2D6 NM, other clinical
laboratories and the DPWG guidelines consider an AS of
1.0 as CYP2D6 IMs6–8,11 (Table 1). Differences also exist for
the AS value that separates NMs from UMs. Consequently,
the different ways of inferring CYP2D6 phenotype between
laboratories and guidelines can cause discordant CYP2D6
phenotype assignments and, thus, lead to inconsistent
therapeutic recommendations. To minimize confusion, it
is important to maintain standardized CYP2D6 phenotype
translation from genotype data. As such, the purpose of this
project was to harmonize the systems used by the CPIC and
DPWG and reach consensus among an international panel
of CYP2D6 experts regarding the standardization of how to
translate CYP2D6 genotype to phenotype.
MATERIALS AND METHODS
The Delphi survey technique is an established approach
for seeking expert consensus on a given topic.12–14 The

Figure 1 Process for translation of CYP2D6 genotype to phenotype. Diplotype describes the combination of two alleles (or
haplotypes), which can involve multiple variants. Diplotype and genotype, a term that technically describes variation at a single
nucleotide polymorphism (SNP), are often used interchangeably. Because genotype is the more commonly used term, it is used
throughout this report. AS, activity score.
Table 1 Comparison of systems used for CYP2D6 genotype to phenotype translation
CPIC

DPWG

>2

> 2.5

System 1a (n = 1)

System 2 (n = 1)

System 3 (n = 3)

System 4 (n = 1)

>2

Not tested

1.5−2

1b to 2

0.5−1

0.5−1b

0

0

AS
UM
NM to UM
NM

1−2

1.5−2.5

0.5

0.5−1

0

0

IM to NM
IM
PM to IM
PM

≥3

≥3

2.25 < x < 3

2.5

1.75 ≤ x ≤ 2.25

2

1.25 < x < 1.75

1.5

0.75 ≤ x ≤ 1.25

1

0 < x < 0.75

0.5

0

0

AS, activity score; CPIC, Clinical Pharmacogenetics Implementation Consortium; DPWG, Dutch Pharmacogenomics Working Group; IM, intermediate metabolizer; NM, normal metabolizer; PM, poor metabolizer; UM, ultrarapid metabolizer.
AS ranges shown in gray are not reported. n refers to the number of laboratories that reported using the system.
a
This laboratory utilizes a propriety system of values to determine AS. bNM AS = 1 is a combination of a fully functional allele plus a no function allele; IM
AS = 1 is a combination of two decreased function alleles.
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method uses a series of repeated structured questionnaires or “rounds.” Each round provides written, systematic refinement of expert opinion, where feedback of group
opinion is provided after each round.15 Delphi survey technique guidelines proposed by Hasson et al.16 were consulted in the design of the project. The method used is this
study is often referred to as a “modified-Delphi” as a major
modification to the Delphi technique consists of beginning
the process with a set of carefully selected options vs. an
open-ended questionnaire.
For the Delphi method used (Figure 2), CYP2D6 expert
members of the CPIC and DPWG were solicited by email
invitation, as well as other international investigators with
published expertise in CYP2D6 PGx. In addition, experts
were solicited by posting a description of the project on the
PharmGKB and CPIC websites.
Experts were invited to participate in a series of surveys
using an internet-based survey tool (SurveyMonkey, Palo
Alto, CA; http://www.surve
ymonk
ey.com), supplemented
with multiple live webinars that were used to explain the
survey and solicit feedback. The webinars were designed
to facilitate understanding of the survey to encourage completion; toward the end of the process an additional webinar
was used to assist in developing consensus. Each survey
also included questions regarding the expert’s workplace
setting and degree of CYP2D6 expertise (i.e., role in clinical
PGx, time devoted to CYP2D6). Responses were included in
the analysis if the respondent provided their name and contact information, which were necessary to enable follow-up
with the respondent for the subsequent round (but not disclosed). Responses were tabulated as numeric counts and
frequencies for each phase to determine whether consensus
was reached. Consensus was defined as 70% of experts

agreeing; this level of agreement has been considered appropriate in previous Delphi studies.17–19
Phase 0: Assessment
The objective of the assessment phase was to define
areas of discordance among assignments of CYP2D6
phenotype based on genotype. The Genetic Testing
Registry 20 was queried for laboratories performing clinical CYP2D6 genetic testing, and emails requesting participation in a survey were sent to each laboratory. The
survey consisted of 16 questions regarding CYP2D6
genotype interpretation, including questions regarding
current methods used to translate CYP2D6 genotype to
phenotype (see ref. 21 for the laboratory survey questions). Clinical practice guidelines (CPIC and DPWG) were
evaluated for systems used to translate genotype to phenotype. References used in the evidence tables of the
CPIC guidelines and additional literature were evaluated
for differences in AS between 0.5 vs. 1 and 1 vs. 2, and
consequences of CYP2D6*10-containing genotypes on
AS assignment. Results were presented to the CYP2D6
experts on the first conference call.
Phase I: Development
The objective of the development phase was to determine
CYP2D6 genotype to phenotype translation options for
evaluation and assess initial expert opinions on current systems being used by clinical laboratories and available PGx
guidelines. Given that the discordance between genotype
to phenotype translation is mostly related to the AS of 0.5,
1, and 2 and disagreements regarding the activity value assigned to CYP2D6*10, the first expert conference call provided examples of pharmacokinetic studies with AS data

Figure 2 Modified Delphi process. aComments from each round were made available to all experts and discussed on conference
calls. AS, activity score.
Clinical and Translational Science
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and additional studies comparing CYP2D6*10 activity (see
ref. 21 for this spreadsheet). Experts were required to either
attend the live conference call or to listen to the recorded
version and asked to provide feedback and additional references if warranted.
Phase II: Prioritization
The expert opinions discussed in the development phase
were used to inform the prioritization phase with the final
objective to select a genotype to phenotype translation
system to which at least 70% of the experts agreed upon.
Survey 1 asked specifically if experts thought there was a
clinically significant difference between AS of 1 vs. 2 and
0.5 vs. 1, and if there was a rationale to use a lower activity
value for AS calculation (i.e., “downgrade” the activity value
from 0.5 to 0.25) for some CYP2D6 alleles (e.g., CYP2D6*9,
*10, *17, *29, and *41) to more accurately reflect activity
relative to other CYP2D6 alleles. Survey 1 also presented
five different systems for translating CYP2D6 genotype to
phenotype to assess expert opinion of each system. All
questions required expert explanation, references, and examples to support the opinion. The results from Survey 1
were presented on a conference call and discussed, and a
subsequent call presented two methods for assigning AS
(i.e., AS ordinal groups vs. continuous percentage activity values). The results from Surveys 2 and 3 were used to
prioritize one method to move into the refinement phase.
Results including expert comments from previous surveys
were provided with each survey.
Phases III and IV: Refinement and consensus
Based on the results from Survey 3, Surveys 4−6 were used
to refine the details of the selected approach. Experts were
asked a series of questions related to AS definitions for
each CYP2D6 phenotype. A summary of comments from
previous surveys was provided and experts were asked to
review the comments prior to responding to subsequent
questions.
Phase V: Validation
Once consensus was reached, results were presented on
a member-wide CPIC call and posted to the CPIC website for 2 months to allow for public comment. PharmGKB
also blogged about the project and solicited feedback.
Feedback was presented to the experts on a subsequent
conference call and discussed. Survey 7 measured acceptance of incorporation of the feedback into the previous
consensus system. The final survey (Survey 8) measured
the level of acceptance of the final CYP2D6 genotype to
phenotype translation system.
RESULTS
Expert panel composition
A total of 37 CYP2D6 experts participated in the project
with 27 completing Survey 1, 28 completing Survey 2, 24
completing Survey 3, 25 completing Survey 4, 27 completing Survey 5, 31 completing Survey 6, 23 completing Survey
7, and 27 completing Survey 8. Not all experts participated
in each round and some experts participated in the initial or
early rounds but not in the later rounds or vice versa. The

participants represented a diverse group of self-identified
experts with varying levels of CYP2D6 expertise (Table 2)
and an international representation: 59% were from the
United States, 27% from Europe, and 11% from other countries (i.e., South Korea, Japan, Canada, and Australia). The
study was facilitated by representatives from both the CPIC
(n = 5) and the DPWG (n = 3) leadership.
Phases 0 and I: Assessment and development
Email invitations were sent to 43 clinical testing laboratories
who reported performing CYP2D6 genotype testing to the
Genetic Testing Registry. A total of 15 laboratories completed a survey regarding how their laboratory translated
CYP2D6 genotype to phenotype. Of those, 47% (n = 7) reported using the CPIC method for translating CYP2D6 genotype to phenotype (i.e., AS of 1.0 is classified as NM). Of
the eight laboratories (53%) not using the CPIC method (i.e.,
AS of 1.0 is classified as IM), six disclosed their CYP2D6
genotype to phenotype translation methods (Table 1). Full
results can be found in ref. 21. Experts participated in an
initial conference call during which results from the laboratory survey were reported, evidence supporting differences
in AS of 0.5, 1, and 2 was presented, and available information regarding CYP2D6*10 activity was shared. Finally,
options for a system for translating genotype to phenotype
were discussed.
Phase II: Prioritization
In Survey 1, 93% (n = 25) of the experts agreed that there is
a clinically significant difference between a CYP2D6 AS of 1
and 2, and 78% (n = 21) agreed that there also is a significant
difference between an AS of 0.5 and 1. Among the experts
agreeing to the need to downgrade some alleles to an activity value of 0.25 (53%; n = 14), 85% selected CYP2D6*10
and 50% selected CYP2D6*41. Based on the first conference call discussion, Survey 1 included five potential options to move forward (Supplemental Figure S1). However,
no method reached consensus (> 70%). Comments and
Survey 1 results were made available to all participants and
discussed on the second conference call. Based on feedback provided after the second call, a third call was held
to discuss using a “percentage activity system” vs. the AS
Table 2 Key demographics of CYP2D6 experts
No. (%)
respondents (n = 37)
Workplace setting
Laboratory test interpretation

3 (8)

Nonprofit or academic hospital

14 (38)

Reference/clinical laboratory

7 (19)

Research or clinical institute
University

3 (8)
10 (27)

Time related to work involving CYP2D6
0–5%

2 (5)

6–25%

16 (43)

26–50%

11 (30)

51–75%

6 (16)

76–100%

2 (5)
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system (see Discussion). After receiving feedback from several of the experts, the CPIC and the DPWG recommended
to the experts to proceed with the use of the AS system to
which 94% (n = 29) agreed in Survey 2. Also in Survey 2,
42% (n = 12) preferred a system that classifies AS of 0.5 and
1 as IMs, 38% (n = 11) preferred to create a new phenotype
group for AS of 1, 7% (n = 2) thought both methods would be
acceptable, and 14% (n = 4) recommended another method.
Experts were asked to provide their rationale for their responses and Survey 2 results were discussed on a conference call. Survey 2 results can be found in ref. 22. Based on
the conference call discussion and Survey 2 results, CPIC
and DPWG representatives recommended to proceed with
the use of AS and to downgrade the activity value of some
alleles (currently limited to CYP2D6*10). Using an activity
value of 0.25 for AS calculation to more accurately reflect
the considerably decreased activity of CYP2D6*10 results
in the introduction of additional AS groups. In Survey 3, the
majority of experts (96%) agreed to create an activity value
of 0.25 category, and 88% agreed to the assignment of AS
0.5−1 as an IM.

Phase V: Validation
After 2 months of accepting public comments, 2 issues
were revisited for consideration: (i) inclusion of a rapid metabolizer (RM) phenotype group between NM and UM; and
(ii) use of contiguous AS values to define each phenotype
(i.e., no gaps between AS categories). After discussion on
a conference call and Survey 6, 87% (n = 20) of the experts rejected the introduction of an RM phenotype group,
whereas 70% agreed to use contiguous AS ranges to define CYP2D6 phenotype based on genotype. Experts were
also asked regarding the range for PMs: the majority (61%;
n = 14) favored to define PMs as having two no function
alleles (AS = 0), 30% (n = 7) favored defining AS ≤ 0.25 as
PMs, and 9% indicated “I do not know.” Results were discussed on a subsequent conference call on which the experts also discussed and agreed on the contiguous ranges
for the other phenotype groups (Survey 7; 82% of the participants (n = 22) agreeing to the final assignments shown
in Table 3).

Phases III and IV: Refinement and consensus
Surveys 4 and 5 were used to refine the new system discussed above. Specifically, the experts discussed how to
integrate the new AS groups (i.e., 0.25, 0.75, 1.25, 1.75, and
2.25) that are introduced by the addition of an activity value
of 0.25 for AS calculations into the four phenotype categories (i.e., PM, IM, NM, and UM). As shown in Supplemental
Table S1, Survey 5 included two options. Fourteen (52%)
of the experts chose option 1, 11 (41%) chose option 2,
and 2 (7%) disagreed with both options. Because the experts favored option 1 (52% vs. 41%), the CPIC and DPWG
representatives recommended option 1 on Survey 6; this
decision was supported by expert comments regarding
the small contribution of an AS of 0.25 to clinically appreciable activity to the overall function. Experts agreed with
the option and consensus was reached (27 (87%) agreed,
whereas 4 experts (13%) disagreed; Table 3).

We engaged a diverse group of international CYP2D6 experts to establish a standardized method for translating
CYP2D6 genotype to metabolizer phenotype. The major
focus of this working group was to harmonize how to
translate CYP2D6 genotype into phenotype; a secondary
aim was to explore how currently used systems could be
improved. This international group of experts consisted of
representatives of academia and industry, including clinical genetic testing laboratories. In addition, individuals with
experience in implementing CYP2D6 PGx into clinical practice and electronic health records at large hospitals were
included to assess the impact of the project on past or ongoing CYP2D6 implementation efforts. Importantly, the final
CYP2D6 translation method presented in Table 3 will be
incorporated into the CYP2D6 tables on www.cpicpgx.org
and used in all new and updated CPIC and DPWG guidelines. We also recommend that this system be considered

DISCUSSION

Table 3 Final consensus CYP2D6 genotype to phenotype translation compared to previously reported CPIC and DPWG methods
Inferred
CYP2D6
phenotype

Previous CPIC
definition (AS)

Previous DPWG
definition (AS)

Consensus
definition (AS)

Consensus contiguous
definition (AS)

Examples of CYP2D6 diplotypes for
consensus translation method
*1/*1xN, *1/*2xNb , *2a /*2xNb , *1x2/*9

UM

>2

> 2.5

> 2.25

> 2.25

NM

1–2

1.5–2.5

1.25

1.25 ≤ x ≤ 2.25

*1/*41, *1/*9

2.0

*1/*1, *1/*2
*2x2/*10

2.25
IM

0.5

0.5–1

0.25

0 < x < 1.25

0

0

*4/*10
*4/*41, *10/*10

0.5

PM

*1/*10

1.5

0.75

*10/*41

1

*41/*41, *1/*5

0

0

*3/*4, *4/*4, *5/*5, *5/*6

AS, activity score; CPIC, Clinical Pharmacogenetics Implementation Consortium; DPWG, Dutch Pharmacogenomics Working Group; IM, intermediate metabolizer; NM, normal metabolizer; PM, poor metabolizer; UM, ultrarapid metabolizer.
a
CYP2D6*2 is currently considered to be a normal function allele by CPIC and DPWG; however, this function assignment has been challenged32 and some
laboratories report CYP2D6*2 function differently. Function of this allele will be reassessed as additional data become available. bN is categorical and indicates the number of copy variants (e.g., *1x2, *1x3, etc).
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as standard practice across all areas of clinical PGx, including clinical genetic testing laboratories. We also strongly encourage PGx researchers to use this standardized method
to report their findings as this will greatly facilitate future
data collection from the literature and comparison of data.
Throughout the project several issues and challenges
were identified and discussed in detail (Table 4) as follows. (i) Lengthy discussions entailed the possibility of
generating a new phenotype group for AS = 0.5 as patients with genotypes consisting of one decreased and
one nonfunctional allele seem to have lower activity compared with those with genotypes giving rise to an AS of 1.
Concerns were raised that combining AS of 0.5 and 1.0 in
research studies may mask potentially significant differences among these AS groups because there are considerably fewer subjects with an AS of 0.5. The introduction
of a new phenotype group describing patients between
PM and IM was, however, rejected by the CPIC and DPWG
representatives based on the CPIC term standardization
project, which determined that five phenotype groups are
sufficient18; the majority of experts also rejected the introduction of an additional phenotype group. (ii) A number
of factors weighed into the decision to reclassify AS of 1
from NM to IM. Because published studies vary on how
subjects with an AS of 1 are grouped (NM vs. IM), it is
difficult to compare AS of 0.5–1 vs. 2 or AS of 1 vs. 2 with
confidence to support differences in outcomes between

these groups. In addition, more laboratories also currently
classify an AS of 1 as IMs and not NMs (Table 1), indicating that classifying an AS of 1 as IM may be minimally
disruptive to most research and clinical laboratories. (iii)
Although the goal is to have a translation system that is
agnostic to the drug used, the experts realized that certain genotypes may need recommendations that differ
from their “drug-agnostic” phenotype group assignment.
To address this challenge, recommendations from the
CPIC and the DPWG can be different for certain drugs
(see CYP2D6*10-containing genotypes in CPIC tamoxifen guideline for example3), or for a particular AS group
if warranted. In other words, a recommendation can be
based on the AS vs. the phenotype group. Therefore, it is
extremely important that clinical laboratories not only report phenotype but also detail the patient’s genotype and
sequence variations tested (see Bousman et al.22 for guidance of how to select a PGx test).
A secondary goal of the project was to re-evaluate the
activity values assigned to alleles with decreased function.
Currently, a value of 0.5 bins decreased function alleles
together regardless of the percentage activity they retain
compared to the CYP2D6.1 (wild-type) protein product. The
majority of values used today for AS calculation are based
on the original report by Gaedigk et al.10 that was published
11 years ago. The prospect of lowering the value assigned
to CYP2D6*10, an allele that is anecdotally known to have

Table 4 Discussion points raised by CYP2D6 experts during Delphi process
Discussion points

Pros

Cons

Addition of CYP2D6 RM
phenotype

• Certain genotypes may have increased activity compared
to NMs but less than UMs
• Addition of RM group would be in alignment with
CYP2C19

• Not enough evidence to differentiate between two
increased function phenotypes (RM vs. UM) and not clinically useful

Addition of new
phenotype group
between IM and PM

• Combining AS of 0.5 and 1.0 in research studies may
mask potentially significant differences among these AS
groups

• Many studies combine AS of 0.5 and 1.0 into one phenotype group
• Majority of experts rejected the addition of an additional
phenotype group
• May not be clinically useful and would be outside the
terms developed in the term standardization project18

Changing AS of 1 from
NM to IM

• More likely accepted by experts
• More clinical laboratories are already reporting an AS of
1.0 as an IM
• Providing recommendations for a “normal metabolizer”
is confusing and currently two CPIC guidelines provide
separate recommendations for AS of 1.0

• Institutions and laboratories following the CPIC guidelines
will need update this phenotype translation and potentially re-contact previously tested patients to inform them
of the phenotype change with any associated clinical
recommendations

Creation of new activity
value (0.25)

• CYP2D6*10 has been characterized as an allele conveying
significantly decreased function across substrates
• More flexibility for assigning AS and, therefore,
recommendations

• Institutions and laboratories following the CPIC guidelines
will need to update this phenotype translation and potentially re-contact previously tested patients to inform them
of the phenotype change with any associated clinical
recommendations

Contiguous AS scale

• Can accommodate any future values of AS

• No currently used activity scores fall in between the
already listed ranges (e.g., there is no AS of 0.1)

Percentage activity
system

• May be more intuitive to clinicians
• May be more accurate

• Little to no data exist for the vast majority of alleles to
discriminate activity on a scale of 0.1 (10% increments)
• Broad range of interindividual variability among subjects
within the same genotype group
• Percent activities may still need to be translated into a
limited number of phenotyping categories in order to follow the CPIC and/or DPWG guidelines

AS, activity score; CPIC, Clinical Pharmacogenetics Implementation Consortium; DPWG, Dutch Pharmacogenetics Working Group; IM, intermediate metabolizer; NM, normal metabolizer; PM, poor metabolizer; RM, rapid metabolizer; UM, ultrarapid metabolizer.
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“little” activity was reviewed earlier, but the authors did not
find sufficient evidence to downgrade this allele based on
evidence available 6 years ago.23 Since then, there was
mounting evidence suggesting that CYP2D6*10 not only consistently conveys decreased function across substrates, but
also seems to be, on average, considerably lower compared
with other decreased function alleles. Thus, using an activity
value of 0.5 for AS calculation for CYP2D6*10-containing
genotypes may overestimate the metabolic capacity of patients with CYP2D6*10/*10 or *10/no function genotypes.
Assigning an activity value of 0.25 to the CYP2D6*10 allele
for AS calculation will group CYP2D6*10/*10 as AS = 0.5
and *10/no function as AS = 0.25 (opposed to AS = 1 and
AS = 0.5, respectively), which more precisely aligns with the
level of reduction of enzyme activity.
Notably, there are other star (*) alleles that harbor the
CYP2D6*10 defining variant (100C>T; rs1065852) in combination with other variants that, to the best of current knowledge, do not impact function or have decreased function on
their own (e.g., 1023C>T), which are currently classified by
the CPIC as “decreased” function and, thus, receive a value
of 0.5 for AS calculation (e.g., CYP2D6*49, *54, *65, and *72).
Note that positions are provided according to the genomic
CYP2D6 RefSeq NG_008376.3, the numbering system recommended by PharmVar.24 There are also a number of alleles with g.100C>T that are currently labeled as “uncertain”
function (e.g., *37, *52, *64, *87, *94, and *95). Most experts
recommended that these alleles should also receive an activity value of 0.25; however, concerns were raised by some of
the experts regarding the lack of evidence (i.e., in vitro or in
vivo studies) for most of these alleles (e.g., 100C>T in combination with other SNP(s) may obliterate function, or compensate for the decreased function caused by 100C>T).10,25
Thus, other CYP2D6 alleles containing the 100C>T variant
besides *10 will be assessed as part of future CPIC guideline
development. At that time, functional status and values for
AS calculations will be assigned for these alleles; other alleles
will also be reviewed and re-assessed during this process.
It was also discussed whether genotype to phenotype
translation should be standardized across all CYP450 enzymes. Currently, the AS is applied to CYP2D6 for which it
was originally devised to accommodate a large (and growing) number of alleles with varying activity and was widely
adopted after being published10; hence, it was a natural
decision for the CPIC to adopt this system. The AS was
eventually also adopted for DPYD gentoype to phenotype translation to accommodate the vast number of sequence variants that emerged for this gene. As shown in
Supplemental Table S2, other CYP genes have their distinct systems to translate genotype to phenotype. There was
no consensus among the group whether this would be a desirable goal because a major revision toward a CYP-wide
system may pose a major challenge for clinical reporting and
implementation with unclear benefits.
Feedback included the suggestion to add an RM phenotype group. One argument for having an RM phenotype
group was that certain genotypes may have increased activity compared with NMs (e.g., *1x2/*41), but less than UMs
(e.g., *1x2/*2); it was also argued that the introduction of an
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RM group would be in alignment with CYP2C19. However,
the experts felt that there was not enough evidence to differentiate between two “increased function” phenotypes (rapid
and ultrarapid) for CYP2D6 and, thus, these groups would
not be clinically useful.
In 2016, the CPIC published a consensus project aimed
to standardize terms describing allele function and phenotype.18 Prior to this project, various terms were used
for allele function and phenotype, which impeded reporting and sharing of test results across clinical laboratories
and electronic health records. Based on the results of this
project, Systematized Nomenclature of Medicine-Clinical
Terms (SNOMED-CT) and Logical Observation Identifiers
Names and Codes (LOINC) terms were created for use in
the electronic health record to facilitate efficient reporting
of PGx results. Although the 2016 project did not address
standardization of the translation of genotype to phenotype,
PGx experts were asked whether they favor a four or five
major category phenotype system. The majority of participants (91%; n = 48) agreed to four categories (see all survey
results in ref. 21). The CYP2D6 experts and CPIC and DPWG
representatives considered this result suggesting that adding an additional phenotype category may not be widely accepted by the PG community.
The use of a contiguous AS scale for defining metabolizer
phenotype was addressed at two stages during the Delphi
process. Early in the process (call #3, Survey 2), a group of
experts advocated for an alternative system referred to as
the “percentage activity” system. Similar to the AS, in the
percentage activity system, each allele is assigned a value
on the scale of 0 (no activity) to 1 (normal activity); however,
in the percentage activity system, values are assigned in increments of 0.1 instead of 0.5 (now 0.25; Figure 3). In addition, instead of calculating the sum of the two activity values
to calculate the AS, the values would be averaged and multiplied by 100 for the percentage activity system so that each
patient’s CYP2D6 metabolic capacity is described on a percentage activity scale of 0% (analogous to AS = 0) to 100%
(AS = 2.0) or higher. It was argued that the percentage activity system may be more intuitive to clinicians. Although such
a system may ultimately be more precise, there are a number
of hurdles. For example, the determination of activity for an
allele is difficult as is and to discriminate activity on a scale of
10% increments seems impossible as there are no data for
the vast majority of alleles at this point in time. Second, there
is a broad range of interindividual variability among subjects
within the same genotype group10,25 and third, even if activity
could be determined on a 10% scale, percent activities may
still need to be translated into a limited number of phenotyping categories for feasibility of clinical implementation.
Given these challenges, the experts came to consensus
on Survey 2 to move forward with the AS system mainly due
to limited data for estimating percentage activity of individual
alleles, with a general interest in future work that moves the
field in the direction of more precise activity estimates as well
as the prospect of developing more sophisticated dosing algorithms that are based on population pharmacokinetic and
dynamic models taking genotype along other pertinent factors
into account.
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Figure 3 Comparison of the Clinical Pharmacogenetics Implementation Consortium method and percentage activity method for
translating CYP2D6 genotype to phenotype. Thin lines represent different ways to translate activity score (AS) into phenotype and the
bold lines represent the recommended CYP2D6 genotype to phenotype translation consensus system. IM, intermediate metabolizer;
NM, normal metabolizer; PM, poor metabolizer; UM, ultrarapid metabolizer.

The second discussion of a “contiguous scale” system
was held after the public comment period (Survey 7), after
thresholds for each phenotype had already been agreed
upon. Given the possibility of future allelic re-estimates or
percentage activities, the experts defined the consensus
scale contiguously, such that all potential values of AS have
a consensus phenotype translation. For example, given that
an AS = 0 is PM and an AS = 0.25 is IM, would an AS = 0.2
be a PM or IM? Thus, the contiguous consensus scale
(Table 3) can accommodate any future scores regardless of
the number of groups or system used.
A central aim of this project was to continue the previously
reported and ongoing efforts dedicated to standardizing inconsistent components related to clinical PGx, including
genetic testing, interpretation, recommendations, and implementation.18,26–29 Importantly, we strongly encourage all
PGx stakeholders to adopt the consent CYP2D6 translation
system that has emerged from this project. Broad adoption
of the proposed CYP2D6 translation system by clinical laboratories as well as researchers will ultimately lead to reduced interlaboratory discrepancies, increased consistency
in CYP2D6 reporting, thus more consistent test interpretation. The performance of this system will also be measurable
over time based on the metrics from the College of American
Pathologists Pharmacogenetic Proficiency Survey, as
CYP2D6 genotyping/phenotyping has historically had the
greatest interlaboratory variability among the commonly
tested PGx genes.30 However, we acknowledge that adopting this process, if distinct from a previous reporting protocol, may also result in laboratory cost and effort to modify
workflows and reconcile previously reported CYP2D6 results based on prior translation systems.
Healthcare institutions that have already implemented
CYP2D6 genotyping using the CPIC method will be affected
by this new system as follows: (i) patients with a CYP2D6 AS
of 1.0 who were previously assigned an NM phenotype will
now have to be reassigned an IM phenotype and patients
with a CYP2D6 AS of 2.25 who were previously assigned a
UM phenotype assigned as NM; and (ii) CYP2D6 interpretive reports as well as all applicable educational materials

pertaining to an AS of 1.0 (or 2.25) will need to be updated.
Because the former change will necessitate substantial efforts in order to back-track patients and inform them of their
new phenotype assignment, some institutions may elect not
to inform previously tested patients of their new re-assigned
CYP2D6 phenotype.
The Delphi method is a powerful tool that was developed
to build consensus among and to develop standards across
different disciplines.12,13,15 Key risks to the validity of a
Delphi study include overestimating the expertise of participants and attrition across the consensus rounds. Given that
each participant had some CYP2D6 PGx expertise and 51%
of survey respondents indicated that they spend > 26% of
their time devoted to work related to CYP2D6, we believe
to have had adequate CYP2D6 expertise among our survey participants. Although attrition rates were not defined a
priori, 76% of the experts participated in Survey 7 (participation averaged 74% for Surveys 1–6) and relative to other
Delphi panels and the recommended minimum panel size,
our final consensus panel was relatively large (suggested
minimum for expert panels is 10 participants), which reinforces the validity of our results.31 To reduce bias, especially
the authority or reputation of specific individuals, Delphi
panel participants are often kept anonymous throughout
the process. Although survey creators and analysts were
not blinded to participants, identifying information was not
shared among survey participants. The only occasions of
participant identification were in between surveys when
nonblinded email invitations were sent to participants in
conference calls and webinars during which interim results
were discussed. Because many survey results were close,
the CPIC and DPWG representatives discussed options for
the next survey based on previous results and comments
from the experts, which resulted in recommendations of limited choices to move forward. However, experts still had to
agree to the option.
In conclusion, consensus among an international panel of
CYP2D6 experts regarding the standardization of translating CYP2D6 genotype to phenotype was achieved. Moving
forward, the CPIC and DPWG will use this system in their
www.cts-journal.com
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practice guidelines. As most PGx clinical recommendations
are based on phenotype, we anticipate that broad adoption
of the proposed CYP2D6 genotype to phenotype translation
framework will minimize discrepant CYP2D6 test results and
inconsistent therapeutic recommendations.
Supporting Information. Supplementary information accompanies this paper on the Clinical and Translational Science website (www.
cts-journal.com).
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